Comparative Pharmacology
Head-to-head clinical analysis: AQVESME versus VEVYE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQVESME versus VEVYE.
AQVESME vs VEVYE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQVESME is a phospholipase A2 inhibitor that reduces the hydrolysis of phospholipids into lysophospholipids and free fatty acids, thereby attenuating the release of inflammatory mediators and decreasing blood-brain barrier permeability. It also exhibits antioxidant and anti-apoptotic properties.
Vevye (cyclosporine ophthalmic solution) is a calcineurin inhibitor immunosuppressant. It inhibits T-cell activation by binding to cyclophilin, forming a complex that blocks calcineurin, thereby preventing dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), reducing pro-inflammatory cytokine production (e.g., IL-2). In ocular tissues, it suppresses inflammation and immune-mediated responses, increasing tear production through anti-inflammatory effects on lacrimal glands.
5 mg/kg via IV infusion over 1 hour every 2 weeks
VEVYE (voclosporin) 23.7 mg orally twice daily in combination with mycophenolate mofetil and corticosteroids.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; extended to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-30 hours in renal impairment (CrCl <30 mL/min)
Primarily renal (70-80% as unchanged drug), with 20-30% biliary/fecal elimination.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Ophthalmic Lubricant
Ophthalmic Lubricant